Does Humana Cover Ozempic?
The verdict
Conditional on most plans
Humana covers Ozempic for type 2 diabetes with prior authorization — typically Tier 3 (preferred brand) on Medicare Part D formularies, which means lower cost-share than a non-preferred specialty tier. Ozempic is not covered for off-label weight-loss use under any Humana line of business. Humana's predominantly Medicare membership makes the $2,100 Part D OOP cap and the 2027 IRA price reduction the most operationally important cost facts on this page.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Humana using your member ID.
Key facts
Ozempic is typically Tier 3 (preferred brand) on Humana Medicare Part D formularies for 2026, providing lower cost-share than non-preferred or specialty tiers.
Humana Part D formulary, 2025–2026
The IRA Maximum Fair Price for semaglutide under Medicare is $274 per 30-day supply, effective January 1, 2027 — a 71% discount off the CY2024 list price.
CMS, IRA Drug Price Negotiation Program, 2024
The 2026 Medicare Part D out-of-pocket cap is $2,100, limiting maximum annual beneficiary exposure for covered drugs including Ozempic.
CMS, Medicare Part D Redesign, Inflation Reduction Act
Medicare vs. commercial coverage
Whether Humana covers Ozempic depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Medicare Part D and Medicare Advantage: Humana is one of the largest Part D plan sponsors in the US. Ozempic is typically Tier 3 (preferred brand) on Humana Part D formularies, covered for type 2 diabetes with prior authorization. PA requires a documented T2D diagnosis and documented metformin step therapy (or intolerance/contraindication). The 2026 Part D out-of-pocket cap is $2,100 — limiting maximum annual beneficiary exposure regardless of tier. Starting January 1, 2027, the IRA Maximum Fair Price for semaglutide (Ozempic/Rybelsus/Wegovy) drops to $274 per 30-day supply — a 71% reduction from the CY2024 list price of approximately $959. A separate most-favored-nation pricing track targets $245/month with a $50 beneficiary copay; the two tracks operate independently. Medicare beneficiaries cannot use the NovoCare savings card (federal anti-kickback rules). Ozempic is not covered for off-label weight loss; off-label use is statutorily excluded from Part D.
Commercial / Employer
Group & marketplace plans
Commercial/Employer: Humana's commercial book is limited relative to its Medicare footprint. Where offered, Ozempic is covered for type 2 diabetes with prior authorization and metformin step therapy; not covered for off-label weight loss. Commercially insured T2D patients may be eligible for the NovoCare Ozempic Savings Card ($25 per fill, max $150 per 28-day supply) — verify at NovoCare.com. ACA/Individual: limited Humana ACA presence; covered for T2D with PA where offered. Medicaid: Humana Medicaid MCO plans cover Ozempic for T2D with prior authorization at nominal Medicaid cost-share. Not covered for off-label weight loss. Note: the Medicare GLP-1 Bridge — Humana serves as CMS's central processor — covers Wegovy for weight loss at $50/month outside Part D starting July 1, 2026. That Bridge applies to Wegovy only, not Ozempic.
The 3 boxes you must tick to get approved
Commercial plans that will consider Ozempic require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
Meet all 3 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Ozempic actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
~$1,028/month (Novo Nordisk published pricing, ~$1,027.51 for the 0.25/0.5 mg pen). NovoCare self-pay: ~$199/month intro price (first two fills through December 31, 2026), then ~$349/month (0.25/0.5/1 mg) or ~$499/month (2 mg).
List price with no coverage — before any manufacturer savings card.
With coverage
Medicare Part D: Tier 3 (preferred brand) cost-share varies by plan design; $2,100 OOP cap limits 2026 annual exposure. IRA Maximum Fair Price of $274/30-day for semaglutide takes effect January 1, 2027, a significant reduction for Humana Medicare enrollees. Medicaid: $0–$4 nominal cost-share for T2D use. Commercial: plan-specific tier cost-share — verify on Humana drug lookup.
Typical monthly copay once prior authorization is approved.
Bridge program
NovoCare Ozempic Savings Card: commercially insured T2D patients (not Medicare or Medicaid) may pay as little as $25 per fill (max $150/28-day). Medicare and Medicaid beneficiaries cannot use the card. Note: the Medicare GLP-1 Bridge ($50/month, launched July 1, 2026) covers Wegovy for weight loss — it does not cover Ozempic.
Reduced copay through the assistance program, where eligible.
All figures are estimates. Tier 3 cost-share varies by Humana plan design and benefit phase. Confirm exact cost-share with Humana member services or the Humana drug lookup tool before filling.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Use the Humana drug lookup tool to confirm Ozempic tier
Log in at humana.com or use MyHumana to search for Ozempic under your specific Part D or Medicare Advantage plan. Ozempic is typically Tier 3 (preferred brand) on Humana Part D formularies, but tier and cost-share vary by plan. Confirm prior-authorization requirements and step-therapy criteria for your specific Humana plan.
- 2
Have your prescriber submit prior authorization for T2D
Your prescriber submits the PA through Humana. Required documentation: a documented T2D diagnosis (ICD-10 E11.x), evidence of metformin step therapy (or documented intolerance/contraindication), and the clinical indication (T2D glycemic control or CV/renal risk reduction — not weight management). Bring your A1c history to the PA process; Humana may request it even if no specific threshold is confirmed in the primary PA criteria document.
- 3
Plan for the 2027 IRA price change if you are on Medicare
If you are enrolled in Humana Part D or Medicare Advantage, note that the IRA Maximum Fair Price for semaglutide drops to $274 per 30-day supply on January 1, 2027 — a meaningful reduction from list price. Until then, the $2,100 Part D OOP cap protects against catastrophic cost in 2026. Contact Humana member services for a personalized cost estimate for the current plan year.
Options if Humana won't cover Ozempic
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Rybelsus (oral semaglutide)
Oral semaglutide for type 2 diabetes. Also subject to the IRA Maximum Fair Price of $274/30-day effective January 1, 2027 for Medicare patients. Coverage and tier on Humana plans vary — verify on the Humana drug lookup.
Jardiance (empagliflozin)
SGLT-2 inhibitor commonly used as a step-therapy oral agent before GLP-1 approval. Often a preferred brand tier on Humana Part D formularies with lower cost-share than Ozempic.
Metformin (generic)
Tier 1 on virtually all Humana Part D and Medicaid formularies at $0–$4 copay. Required step therapy before Ozempic PA approval on Humana plans.
Compounded semaglutide (weight-loss seekers only)
For patients seeking semaglutide for weight management — not T2D — who cannot use Humana coverage (which covers Ozempic only for diabetes), compounded semaglutide from $49/mo is available at getcurex.com/cl/glp without insurance. See the offer section below for full disclaimers.
These options are listed for information only — your own clinician decides what is appropriate for you.
❓Frequently Asked Questions
No. Humana does not cover Ozempic for weight loss under any line of business. Ozempic is FDA-approved only for type 2 diabetes — not for weight management. Off-label weight-loss use is excluded by statute from Medicare Part D and not covered on any Humana commercial or Medicaid plan. The Medicare GLP-1 Bridge that Humana processes covers Wegovy for weight loss — not Ozempic. Patients seeking semaglutide for weight management cannot use Humana coverage for Ozempic.
Ozempic is typically Tier 3 (preferred brand) on Humana Part D formularies for 2026, which provides lower cost-share than a non-preferred or specialty tier. Tier placement can vary across Humana's many regional Part D plan designs. Log in to your Humana member account or use the Humana drug lookup to confirm the tier and cost-share for your specific plan, as the Tier 3 classification is a common pattern but not universal across all Humana Part D offerings.
No, if you are enrolled in Humana Medicare Part D or Medicaid. Federal anti-kickback rules prohibit Medicare and Medicaid beneficiaries from using manufacturer savings cards, including the NovoCare Ozempic Savings Card. Since Humana's predominant enrollment is in Medicare and Medicaid, most Humana members cannot use the card. Commercially insured T2D patients on a limited Humana commercial plan may be eligible ($25/fill, max $150/28-day) — verify at NovoCare.com.
If you are enrolled in Humana Medicare Part D or Medicare Advantage, the IRA Maximum Fair Price for semaglutide (Ozempic, Rybelsus, and Wegovy combined) drops to $274 per 30-day supply effective January 1, 2027 — a 71% reduction from the CY2024 list price of approximately $959. A separate most-favored-nation pricing track targets $245/month with a $50 beneficiary copay; both tracks operate independently. In 2026, the $2,100 annual Part D OOP cap still protects against catastrophic costs. Contact Humana for a personalized cost estimate.
These are two separate coverage tracks. The Medicare GLP-1 Bridge — for which Humana serves as CMS's central processor — covers Wegovy for weight loss at $50/month starting July 1, 2026, operating outside Part D. Ozempic under Humana Part D is a separate, standard Part D benefit covering Ozempic for type 2 diabetes with PA and Tier 3 cost-share. Ozempic is not a Bridge-eligible drug; the Bridge targets weight loss and uses Wegovy formulations only.
Related Articles
Does Aetna Cover Vyvanse? 2026 CVS Caremark Formulary
Aetna covers Vyvanse via CVS Caremark — generic lisdexamfetamine preferred, brand non-preferred. 70 mg/day QL per Policy 5.60.024; age-22 PA required.
Read moreDoes Aetna Cover Prolia? CVS Caremark Medical Benefit | Curex
Aetna covers Prolia under the medical benefit with PA — a q6-month clinic injection, not Part D. Jubbonti biosimilar now preferred on CVS Caremark.
Read moreDoes Anthem Cover Adderall? 2026 Coverage Guide | Curex
Anthem covers Adderall through CarelonRx — generic preferred, brand non-preferred. Step therapy may apply on some plans. Verify your Anthem plan.
Read moreDoes Anthem Cover Contrave? 2026 Brand Coverage Guide | Curex
Anthem covers Contrave only if your plan has a weight-loss benefit. Many plans carve it out. CurAccess ~$99/mo is often the fastest path.
Read moreDoes Aetna Cover Contrave? 2026 CVS Caremark Guide | Curex
Aetna (CVS Caremark) often excludes Contrave under AOM carve-outs. Where covered, CVS BMI prior auth applies. Medicare bars it by law. CurAccess ~$99/mo.
Read moreDoes Aetna Cover Forteo? 2026 Coverage Guide
Aetna (CVS) often excludes brand Forteo in favor of generic teriparatide or Bonsity. Teriparatide is covered with PA and bisphosphonate step therapy. 2026.
Read moreInsurance won't cover Ozempic for weight loss — here's a path that doesn't need it
Humana Part D covers Ozempic for diabetes — not weight loss. Medicare beneficiaries cannot use the Novo Nordisk savings card, and the Medicare GLP-1 Bridge covers Wegovy only. Patients who want semaglutide for weight management without Medicare coverage can access compounded semaglutide from $49/mo at getcurex.com/cl/glp — no insurance required. Compounded semaglutide is not the same medication as Ozempic or Wegovy. Compounded tirzepatide is also available from $149/mo. Prescription required, subject to provider review.
- Medication + free shipping
- 24/7 provider access
- Medical intake & prescription review
Compounded semaglutide and tirzepatide are not the same medications as Ozempic and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.
This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Humana before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Ozempic and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.